

32. Bölüm

COVID-19 PANDEMİSİNDE AGRESİF LENFOMALARDA HASTA YÖNETİMİ

Mesut TIĞLIOĞLU¹

GİRİŞ

Yeni korona virüs hastalığı-2019 (COVID-19), 11 Mart 2020’de Dünya Sağlık Örgütü (DSÖ) tarafından pandemi ilan edilmiştir ¹. Hastalık, hafif viral enfeksiyon semptomlarından mortaliteye kadar uzanan geniş bir klinik seyir yelpazesi sunmaktadır. Hipertansiyon, diyabet, kronik obstrüktif akciğer hastalığı veya kanser gibi komorbiditesi olan hastalarda, klinik daha agresif seyretmekte ve enfeksiyona bağlı ölüm daha sık görülmektedir ^{2,3}. Literatürde, ortalama mortalite oranı %4 ila %15 arasında değişmektedir ⁴⁻⁶.

Yapılan çalışmalarda, COVID-19 tanısı alan hastaların %2’sinde alta yatan malignite mevcuttur ⁷. Bu hastaların prognozu, özellikle hematolojik malignitesi olan hastalarda genel popülasyona göre daha kötüdür ⁸.

Lösemi, lenfoma, multiple myelom gibi hematolojik malignitesi olan hastalar, antikanser tedavi, palyatif tedavi, antibiyoterapi, kan transfüzyonu vs. nedenlerle hastaneye sık başvurmaktadır. Ayrıca myelosüpresyon, antikanser tedavilerin yan etkileri, araya giren enfeksiyonlar gibi nedenlerle hastanede yatış süreleri de uzamaktadır ⁹. Tüm bunlara ek olarak hem hastalığın biyolojisinden kaynaklanan, hem de verilen spesifik tedavilere bağlı immünsüpresyon; bu hastalarda COVID-19 riskini arttırırken ayrıca enfeksiyona yakalanma durumunda koronavirus enfeksiyonunun daha mortal seyretmesine de neden olmaktadır ¹⁰. Bu

¹ Dr. Mesut TIĞLIOĞLU, Ankara Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, drmesuttiglioglu@gmail.com

COVID-19 salgını tüm dünyayı etkilemeye devam etmektedir ancak hasta bazında edinilen tecrübeler, literatüre girmeye devam eden yayın ve derlemeler ile elimiz de her geçen gün kuvvetlenmektedir.

KAYNAKLAR

1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The lancet*. 2020;395(10229):1054-1062.
2. Meng Y, Lu W, Guo E, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. *Journal of hematology & oncology*. 2020;13(1):1-11.
3. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *International Journal of Infectious Diseases*. 2020;94:91-95.
4. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *Jama*. 2020;323(18):1775-1776.
5. Guan W-j, Liang W-h, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *European Respiratory Journal*. 2020;55(5)
6. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *New England journal of medicine*. 2020;
7. Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: lessons from a pooled meta-analysis. *JCO global oncology*. 2020;6
8. Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. *Cancer discovery*. 2020;10(7):935-941.
9. Isidori A, de Leval L, Gergis U, Musto P, Porcu P. Management of patients with hematologic malignancies during the COVID-19 pandemic: practical considerations and lessons to be learned. *Frontiers in Oncology*. 2020;10
10. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. *The Lancet Haematology*. 2020;7(10):e737-e745.
11. Al-Naeeb AB, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. *Bmj*. 2018;362
12. Morin RD, Marra MA, Gascoyne RD, Connors JM. Biomarkers for non-hodgkin lymphomas and uses thereof. Google Patents; 2015.
13. Ljungman P, Mikulska M, de la Camara R, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. *Bone marrow transplantation*. 2020;55(11):2071-2076.
14. Gavillet M, Klappert JC, Spertini O, Blum S. Acute leukemia in the time of COVID-19. *Leukemia research*. 2020;92:106353.
15. Di Ciaccio P, McCaughan G, Trotman J, et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. *Internal medicine journal*. 2020;50(6):667-679.
16. Griffiths EA, Alwan LM, Bachiashvili K, et al. Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. *Journal of the National Comprehensive Cancer Network*. 2020;1(aop):1-4.
17. Weinkove R, McQuilten ZK, Adler J, et al. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. *Medical Journal of Australia*. 2020;212(10):481-489.
18. Seval GC, TopÇuoĞlu P, Demİrler T. Treatment Approaches for Managing Patients with He-

- matological Malignancies in the Time of COVID-19 Pandemic. *Turkish journal of medical sciences*.
19. Lang N, Kuruvilla J. Evolving management strategies for lymphomas during the COVID-19 pandemic. *Leukemia & lymphoma*. 2021;62(5):1046-1056.
 20. Dreyling M, Aurer I, Federico M, et al. EHA/ESMO clinical practice guidelines for the management of malignant lymphoma: recommendations for the second phase of the COVID-19 pandemic. 2021;
 21. Cengiz Seval G, Topçuoğlu P, Demirer T. Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic. *Turkish journal of medical sciences*. Mar 12 2021;doi:10.3906/sag-2101-276
 22. Ranjana Advani MNB, MD; Ann LaCasce, MD, MSc; Leo Gordon, MD; Peter Johnson, MD, FRCP; Kerry Joanne Savage, BSc, MD, MSc; Laurie Sehn, MD, MPH; and Jane Winter, MD. COVID-19 and Aggressive Lymphoma: Frequently Asked Questions. *ASH COVID-19 Resources last updated February 5, 2021 version 50*.
 23. Perini G, Fischer T, Gaiolla R, Rocha T, Belleso M, Teixeira L. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH). *How to manage lymphoid malignancies during novel*. 2019;
 24. Chiappella A, Crombie J, Guidetti A, Vitolo U, Armand P, Corradini P. Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? *HemaSphere*. Oct 2019;3(5):e284. doi:10.1097/hs9.0000000000000284
 25. Chan EHL, Koh LP, Lee J, et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. *Cancer medicine*. 2019;8(10):4626-4632.
 26. Yahalom J, Dabaja BS, Ricardi U, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. *Blood*. 2020;135(21):1829-1832.
 27. Percival M-EM, Lynch RC, Halpern AB, et al. Considerations for managing patients with hematologic malignancy during the COVID-19 pandemic: the Seattle strategy. *JCO oncology practice*. 2020;16(9):571-578.
 28. Ljungman P, Styczynski J, Mikulska M, de la Camara R. Coronavirus disease COVID-19: EBMT recommendations. *The European Society for Blood and Marrow Transplantation*. 2020:2020-06.
 29. Perini GF, Fischer T, Gaiolla RD, et al. How to manage lymphoid malignancies during novel 2019 coronavirus (COVID-19) outbreak: a Brazilian task force recommendation. *Hematology, transfusion and cell therapy*. 2020;42:103-110.
 30. Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. *Leukemia & lymphoma*. 2016;57(3):512-9. doi:10.3109/10428194.2015.1110748
 31. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. *Blood, The Journal of the American Society of Hematology*. 2014;124(10):1570-1577.
 32. Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. *Blood, The Journal of the American Society of Hematology*. 2010;116(18):3418-3425.
 33. Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. *Cancer*. 2019;125(9):1507-1517.
 34. Lamure S, Duléry R, Di Blasi R, et al. Determinants of outcome in COVID-19 hospitalized patients with lymphoma: a retrospective multicentric cohort study. *EClinicalMedicine*. 2020;27:100549.